Adecatumumab Biosimilar - Research Grade

Human

EPCAM

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse EpCAM (G8.8) In Vivo Antibody - Low Endotoxin (ICH1217), Edrecolomab Biosimilar - Research Grade (ICH5092)

https://www.imgt.org/mAb-DB/

ICH3002

P16422

Blue ice

ichor.bio's Adecatumumab Biosimilar (Research Grade) is an unconjugated, non-therapeutic research analog of the originator antibody adecatumumab (development code MT201), supplied for research use only and not for clinical or diagnostic application. Adecatumumab is a fully human IgG1 kappa monoclonal antibody directed against the epithelial cell adhesion molecule (EpCAM, CD326), originally developed by Micromet and evaluated in clinical studies in EpCAM-expressing carcinomas including metastatic breast, prostate, and colorectal cancer. This biosimilar reproduces the target specificity and human IgG1 kappa framework of the originator, providing a consistent, well-characterized tool for in-vitro and functional studies of EpCAM biology and antibody engagement, without any therapeutic claim. It is offered at research grade with low endotoxin, and is available in bulk milligram-to-gram quantities to support assay standardization and reproducibility across experiments. Typical applications include EpCAM binding characterization, use as a reference or control antibody, and mechanism-of-action studies such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against EpCAM-positive cell lines. Lot-to-lot consistency makes it suitable as an internal standard for comparability work. EpCAM (epithelial cell adhesion molecule, CD326; gene TACSTD1, UniProt P16422) is a type I transmembrane glycoprotein expressed on the basolateral surface of most normal epithelia and strongly overexpressed on many epithelial carcinomas, making it a widely studied tumor-associated antigen. Beyond its originally described homophilic cell-cell adhesion role, EpCAM participates in signaling: regulated intramembrane proteolysis releases an intracellular domain that, with FHL2 and beta-catenin, can drive proliferation-associated gene expression. EpCAM is also a marker of epithelial and cancer stem-like cells and of circulating tumor cells. Adecatumumab recognizes a relatively membrane-proximal epitope encoded by exon 5 and binds with moderate affinity, a property associated with a wider therapeutic window than higher-affinity anti-EpCAM antibodies. Its intended effector mechanisms against EpCAM-positive cells are ADCC and CDC.

Adenocarcinoma-associated antigen, Cell surface glycoprotein Trop-1, Epithelial cell surface antigen, Epithelial glycoprotein, EGP, Epithelial glycoprotein 314, EGP314, hEGP314, KS 1/4 antigen, KSA, Major gastrointestinal tumor-associated protein GA733-2,

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks